Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review

Sparano, Francesco; Cavo, Michèle; Niscola, Pasquale; Caravita, Tommaso; Efficace, Fabio

doi:10.1007/s00520-018-4137-x

Cited by 22 publications

(20 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent systematic review revealed a paucity of evidence‐based data describing the impact of therapies on symptoms and quality of life in patients with RRMM, identifying an unmet need to better understand patient burden in this population . Findings from two targeted literature reviews suggested that the total cost of illness in patients with RRMM is driven by treatment choice, as well as symptoms, direct costs, productivity loss, and burden on caregivers .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Patient-Reported Factors in Treatment Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

et al. 2019

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…Although direct costs of RRMM have been reported, less is known about patient satisfaction with RRMM therapy, the indirect costs of RRMM, and the impact of disease on caregivers .…”

Section: Introductionmentioning

confidence: 99%

Patient-Reported Factors in Treatment Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

et al. 2019

View full text Add to dashboard Cite

show abstract

“…QoL is also a central component of health technology and cost-effectiveness assessment [21]. Incorporation of QoL endpoints in clinical trials is therefore essential to allow better clinical decisionmaking in patients with MM [22], including those with relapsed/refractory (RR) MM.…”

Section: Introductionmentioning

confidence: 99%

Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data

et al. 2019

View full text Add to dashboard Cite

Background Carfilzomib and daratumumab are licensed in relapsed/refractory multiple myeloma (RRMM), but no headto-head trials have been conducted. Methods We used data from dossiers prepared for the German Federal Joint Committee based on two phase III randomized trials of carfilzomib-based therapies (ASPIRE, ENDEAVOR) and two of daratumumab-based therapies (POLLUX, CASTOR) to conduct a descriptive assessment of health-related quality of life (HRQoL). HRQoL was assessed using the European Organisation for Research and Treatment of Cancer 30-item HRQoL Questionnaire, with hazard ratios calculated for carfilzomib-and daratumumab-based therapy versus comparators for time to HRQoL deterioration of ≥ 10 points. Analyses were also conducted on data from the EORTC 20-item myeloma-specific questionnaire, the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity scale, and the visual analog scale of the EuroQoL 5-dimension, 5-level questionnaire, where results for these instruments were available. As the designs and patient population of the four trials were similar but not identical, the analysis included only indirect, descriptive comparisons. Results Compared with lenalidomide/dexamethasone, median time to deterioration in global health status/QoL was longer for carfilzomib-based therapy versus control, but similar for daratumumab-based therapy and control. Compared with bortezomib/dexamethasone, time to deterioration was significantly longer for carfilzomib-based therapy versus control for global health status/QoL and numerous functional and symptom subscales. HRQoL measurement is feasible in large RRMM populations. Conclusion Descriptive assessment of HRQoL data suggests potential benefits for carfilzomib-based over daratumumabbased therapy.

show abstract

“…For example, a recent study in RRMM patients showed that HRQOL decreased significantly with treatment lines [4]. This evidence is particularly relevant as there is paucity of evidence-based information on PROs in RRMM patients [15].…”

Section: Introductionmentioning

confidence: 99%

Towards the integration of patient-reported outcomes into the global clinical management of multiple myeloma

Niscola

Scaramucci

Efficace

2019

Expert Review of Hematology

Self Cite

View full text Add to dashboard Cite

Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review

Abstract: There is paucity of evidence-based data regarding the impact of therapies on quality of life and symptom burden of patients with RRMM. Inclusion of PRO in future studies of patients with RRMM is needed to better inform clinical decision-making.

Cited by 22 publications

References 49 publications

Patient-Reported Factors in Treatment Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Patient-Reported Factors in Treatment Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data

Towards the integration of patient-reported outcomes into the global clinical management of multiple myeloma

Contact Info

Product

Resources

About